Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
基本信息
- 批准号:7904191
- 负责人:
- 金额:$ 150.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-15 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The San Antonio/Dallas Asthma and Allergic Diseases Cooperative Research Center represents an integrative, collaborative and innovative multidisciplinary effort to investigate the role of a unique Mycoplasma pneumoniae toxin in asthma and related airway diseases. This toxin, designated Community Acquired Respiratory Distress Syndrome Toxin (CARDS TX) remarkably replicates the proinflammatory cytokine/chemokine profiles and histopathology that accompany M. pneumoniae infection. This consortium between The University of Texas Health Science Center at San Antonio and The University of Texas Southwestern Medical School in Dallas combines 4 projects, which focus on basic, clinical and animal modeling strategies, with 2 support cores (administrative and pathology) to bring a totally new approach to defining the relationship between M. pneumoniae and the pathogenesis of asthma. A substantial literature, which has accumulated over thirty-five years, connects M. pneumoniae to onset, exacerbation, and chronicity of asthma, yet no single mycoplasma virulence determinant, or mycoplasma molecule for that matter, has been shown to be a mediator of symptoms and associated pathologies. This lack of definable M. pneumoniae pathogenic factors has greatly hampered an understanding of how M. pneumoniae influences the development and progression of airway diseases. This is especially challenging in complex diseases like asthma, where genetic, immunologic, infectious and environmental variables appear to affect disease development and progression. A major focus of the AADCRC is to directly link the biochemical, molecular and immunological properties of the ADP-ribosylating, vacuolating M. pneumoniae CARDS TX (Project 4), to diagnosis and treatment of asthmatic patients (Projects 3 and 4). By so doing, we hope to demonstrate that CARDS TX is a key mediator of asthma-associated pathobiology in humans (Project 3) and in experimentally infected or intoxicated mice (Projects 1 and 2). Therefore, we intend to (a) directly connect CARDS TX to asthma pathogenesis through novel and effective CARDS TX-targeted diagnostic assessments (ELISA, immunohistochemistry, antigen capture and PCR methodologies) using patient's nasal lavage, sputum and serum samples; (b) use mouse models of M. pneumoniae infection and CARDS TX intoxication to examine both acute and chronic stages of asthma and therapeutic interventions as well as the impact of CARDS TX on airway hyper-reactivity; and (c) further characterize ADP-ribosylating activities of CARDS TX and develop effective and rapid diagnostics to assist in the treatment and control of asthma and related pathologies. The key investigators of each project and core have strong track records and expertise in asthma, airway-related pathologies, immunopathogenesis and M. pneumoniae biology and virulence as well as a history of collaboration and co-publication.
圣安东尼奥/达拉斯哮喘和过敏性疾病合作研究中心代表了一个综合的、协作的和创新的多学科努力,以研究一种独特的肺炎支原体毒素在哮喘和相关气道疾病中的作用。这种毒素,命名为社区获得性呼吸窘迫综合征毒素(CITTX),显著复制了伴随M.肺炎感染。这个由位于圣安东尼奥的德克萨斯大学健康科学中心和位于达拉斯的德克萨斯大学西南医学院组成的联盟结合了4个项目,重点是基础,临床和动物模型策略,2个支持核心(管理和病理学),为定义M.肺炎和哮喘的发病机制。大量的文献,这已经积累了35年,连接M。肺炎支原体与哮喘的发作、恶化和慢性化之间的关系,但没有单一的支原体毒力决定簇或支原体分子被证明是症状和相关病理的介导者。缺乏可定义的M。肺炎支原体致病因子的研究极大地阻碍了对肺炎支原体致病机理的理解。肺炎影响气道疾病的发生和发展。这在哮喘等复杂疾病中尤其具有挑战性,因为遗传、免疫、感染和环境变量似乎会影响疾病的发展和进展。AADCRC的一个主要焦点是将ADP-核糖基化、空泡化M的生物化学、分子和免疫学特性直接联系起来。pneumoniae pneumon通过这样做,我们希望证明,在人类(项目3)和实验感染或中毒的小鼠(项目1和2)中,BTX是哮喘相关病理生物学的关键介质。因此,我们打算(a)使用患者的鼻灌洗液、痰液和血清样品,通过新颖有效的靶向MTX的诊断评估(ELISA、免疫组织化学、抗原捕获和PCR方法学),将MTX与哮喘发病机制直接联系起来;(B)使用M.本发明的目的在于:(a)研究肺炎链球菌感染和肺炎克雷伯氏菌毒素中毒的特征,以检查哮喘的急性和慢性阶段和治疗干预以及肺炎克雷伯氏菌毒素对气道高反应性的影响;以及(c)进一步表征肺炎克雷伯氏菌毒素的ADP-核糖基化活性,并开发有效和快速的诊断方法,以帮助治疗和控制哮喘和相关病理。每个项目和核心的主要研究者在哮喘、气道相关病理学、免疫发病机制和M。pneumoniae生物学和毒力以及合作和共同出版的历史。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOEL Barry BASEMAN其他文献
JOEL Barry BASEMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOEL Barry BASEMAN', 18)}}的其他基金
Role of host cell invasion in Mycoplasma genitalium persistent infection
宿主细胞侵袭在生殖支原体持续感染中的作用
- 批准号:
9197256 - 财政年份:2015
- 资助金额:
$ 150.08万 - 项目类别:
Biochemical, molecular and immunological characterization of Mycoplasma pneumoni
肺炎支原体的生化、分子和免疫学特征
- 批准号:
8328001 - 财政年份:2011
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7914874 - 财政年份:2009
- 资助金额:
$ 150.08万 - 项目类别:
Biochemical, Molecular &Immunological Characterization of the Mycoplasma pneumon
生化、分子
- 批准号:
7686482 - 财政年份:2008
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7274288 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
相似国自然基金
微分动力系统的测度和熵
- 批准号:11101447
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7914874 - 财政年份:2009
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7274288 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
独特的 ADP-核糖基化空泡肺炎支原体毒素 i 的作用
- 批准号:
8300811 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7682873 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
独特的 ADP-核糖基化空泡肺炎支原体毒素 i 的作用
- 批准号:
8705990 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
独特的 ADP-核糖基化空泡肺炎支原体毒素 i 的作用
- 批准号:
8164349 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
独特的 ADP-核糖基化空泡肺炎支原体毒素 i 的作用
- 批准号:
8897848 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
独特的 ADP-核糖基化空泡肺炎支原体毒素 i 的作用
- 批准号:
8513872 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7134895 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别:
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin in asthma
独特的 ADP-核糖基化空泡肺炎支原体毒素在哮喘中的作用
- 批准号:
7480969 - 财政年份:2006
- 资助金额:
$ 150.08万 - 项目类别: